Protagonist Therapeutics, Inc PTGX
We take great care to ensure that the data presented and summarized in this overview for Protagonist Therapeutics, Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PTGX
View all-
Farallon Capital Management LLC San Francisco, CA5.84MShares$262 Million0.98% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$259 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.29MShares$237 Million3.06% of portfolio
-
Bvf Inc San Francisco, CA3.32MShares$149 Million3.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.24MShares$146 Million0.0% of portfolio
-
Johnson & Johnson New Brunswick, NJ2.45MShares$110 Million29.31% of portfolio
-
State Street Corp Boston, MA2.08MShares$93.5 Million0.0% of portfolio
-
Jefferies Financial Group Inc. New York, NY2.04MShares$91.6 Million0.8% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2MShares$89.9 Million0.13% of portfolio
-
Adar1 Capital Management, LLC Austin, TX1.6MShares$72 Million10.49% of portfolio
Latest Institutional Activity in PTGX
Top Purchases
Top Sells
About PTGX
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Insider Transactions at PTGX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 11
2024
|
Asif Ali Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
14,203
-15.74%
|
$624,932
$44.53 P/Share
|
|
Sep 11
2024
|
Asif Ali Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+12.05%
|
$180,000
$15.68 P/Share
|
|
Sep 10
2024
|
William D. Waddill Director |
SELL
Open market or private sale
|
Direct |
8,000
-40.0%
|
$360,000
$45.0 P/Share
|
|
Sep 10
2024
|
William D. Waddill Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+28.57%
|
$96,000
$12.88 P/Share
|
|
Jul 24
2024
|
William D. Waddill Director |
SELL
Open market or private sale
|
Direct |
8,000
-40.0%
|
$320,000
$40.0 P/Share
|
|
Jul 24
2024
|
William D. Waddill Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+28.57%
|
$96,000
$12.88 P/Share
|
|
Jun 13
2024
|
Dinesh V Ph D Patel President and CEO |
SELL
Bona fide gift
|
Direct |
1,000
-0.19%
|
-
|
|
Jun 07
2024
|
Dinesh V Ph D Patel President and CEO |
SELL
Open market or private sale
|
Direct |
35,000
-6.36%
|
$1,225,000
$35.19 P/Share
|
|
Jun 07
2024
|
William D. Waddill Director |
SELL
Open market or private sale
|
Direct |
8,000
-40.0%
|
$280,000
$35.0 P/Share
|
|
Jun 07
2024
|
William D. Waddill Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+28.57%
|
$96,000
$12.88 P/Share
|
|
Apr 18
2024
|
Asif Ali Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,234
-3.21%
|
$30,850
$25.11 P/Share
|
|
Apr 01
2024
|
Dinesh V Ph D Patel President and CEO |
SELL
Open market or private sale
|
Direct |
25,000
-4.35%
|
$700,000
$28.31 P/Share
|
|
Mar 07
2024
|
Harold E Selick Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,490
+18.82%
|
$6,490
$1.89 P/Share
|
|
Mar 01
2024
|
Asif Ali Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
14,248
-14.16%
|
$455,936
$32.28 P/Share
|
|
Mar 01
2024
|
Asif Ali Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+18.56%
|
$144,000
$12.17 P/Share
|
|
Mar 01
2024
|
William D. Waddill Director |
SELL
Open market or private sale
|
Direct |
12,975
-51.95%
|
$402,225
$31.34 P/Share
|
|
Mar 01
2024
|
William D. Waddill Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,975
+34.19%
|
$77,850
$6.09 P/Share
|
|
Mar 01
2024
|
Dinesh V Ph D Patel President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-4.96%
|
$930,000
$31.62 P/Share
|
|
Feb 29
2024
|
Asif Ali Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,939
-10.2%
|
$298,170
$30.81 P/Share
|
|
Feb 26
2024
|
Suneel Gupta Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,282
-2.28%
|
$124,178
$29.53 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 151K shares |
|---|---|
| Exercise of conversion of derivative security | 98.5K shares |
| Payment of exercise price or tax liability | 20.8K shares |
|---|---|
| Bona fide gift | 1K shares |
| Open market or private sale | 248K shares |